Biobank for interstitial lung diseases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to establish a registry and biorepository for patients with interstitial lung diseases (ILD) at the University of Kansas Medical Center. By collecting data and biological samples from patients, the researchers hope to enhance understanding of ILD, identify genetic and environmental risk factors, and discover potential treatment targets. The study will leverage the clinic's extensive patient base to facilitate research into early diagnosis and management of these conditions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. The participant is a patient at TUKHS or has agreed to participate in a study approved by the KUMC Human Research Protection Program (HRPP)
2. The participant is being followed for the presence of autoimmune disease, ILD or other rare lung diseases at TUKHS.
3. The participant is ≥ 18 years of age.
4. The participant has signed an approved consent for this study (living patients only)

Where it's running

• The University of Kansas Medical Center
  Kansas City, Kansas, United States Recruiting

Study contacts

• Principal investigator: Scott Matson, M.D. — University of Kansas Medical Center
• Study coordinator: Kimberly Donnelly, Ph.D.
• Email: kdonnelly@kumc.edu
• Phone: 913-588-6067

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understanding genetic and environmental factors in pulmonary fibrosis

  This study looks at how genes and environmental factors affect pulmonary fibrosis to help understand the disease better for people who have it.

  Recruiting Royal College of Surgeons, Ireland · Dublin · NCT06702228

• Registry for individuals affected by pulmonary fibrosis

  This study invites people with pulmonary fibrosis, along with their caregivers and family members, to share their experiences through online surveys to help researchers understand the condition better and possibly reach out for future studies.

  Recruiting Pulmonary Fibrosis Foundation · Chicago, Illinois · NCT05382572

• Examining muscle function in patients with interstitial lung disease

  This study tests how muscle function affects breathing and exercise in people with interstitial lung disease compared to healthy individuals, and looks at how supplemental oxygen might help.

  Recruiting University of British Columbia · Vancouver, British Columbia · NCT03800017

• AccuPulmo CT Portal for Detecting Pulmonary Fibrosis on Chest CT

  This study tests how well the AccuPulmo CT Portal can identify pulmonary fibrosis on existing chest CT scans from adults at Taichung Veterans General Hospital.

  Recruiting Taichung Veterans General Hospital · Taichung · NCT07761377

• Advanced imaging to see how immunosuppression affects lung fibrosis activity

  This trial will test whether immunosuppression changes PET and MRI measurements of active collagen deposition and tissue injury in people with non‑IPF interstitial lung disease who are starting treatment.

  Recruiting Phase 2 Massachusetts General Hospital · Boston, Massachusetts · NCT07572383

• Identifying biomarkers for progressive pulmonary fibrosis in lung disease patients

  This study is trying to find early signs that can help predict if adults with certain lung diseases will develop progressive pulmonary fibrosis over the next five years.

  Recruiting Amsterdam UMC, location VUmc · Amsterdam, North Holland · NCT06644144

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.